Genespire, a Milan, Italy-based gene-therapy company developing therapies for patients affected by genetic diseases, received an investment from Sofinnova Partners.
The amount of the deal was not disclosed.
The company will use the funds to advance its development efforts.
Led by Professor Luigi Naldini, Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Prof. Alessio Cantore, The Telethon Foundation and San Raffaele Hospital, the company is a spin-off of SR-Tiget, a cell and gene therapy research institute.
This is the third investment for the Sofinnova Telethon Fund, which brought the total financing of Italian startups by Sofinnova Partners to €25m over the past six months. Previous investments include:
- Epsilen Bio, which is developing a technology to turn off genes linked to specific pathologies without irreversibly modifying the DNA (a major potential safety advantage), and
- PinCell, a pre-clinical stage biotech company focused on the development of new therapies for rare dermatological diseases.
The Sofinnova Telethon Fund will continue to invest exclusively in Italy, seeking to identify, create and develop some of the best companies in the field of rare and genetic diseases.